Results from a long-term follow up from the Intergroup Exemestane Study's (IES) data published in the Journal of Clinical Oncology reveals that women's risk of dying from breast cancer can be reduced by changing to an aromatase inhibitor called exemestane after two to three years of tamoxifen treatment...
More...
More...